February 2022

Collaborating Together for Rare Disease

Making the Impossible Possible

Rare diseases and conditions together impact 400 million patients worldwide. As we prepare to recognize Rare Disease Day, advancing therapies for rare diseases remains central to our mission.

As a global team, we share a sense of purpose to excel in every aspect of our work and across every clinical trial so that we positively impact the lives of as many patients as possible. Learn more

Infographic: FDA Expedited Pathways

Veristat regulatory experts created an infographic to highlight the benefits of, qualifying criteria for, and timing and procedures for six different expedited programs and designations. Which of the FDA’s different programs do you qualify for? Learn more.     

Conference Presentation: Operational Challenges of Natural History Trials

Veristat Sr. Project Manager Kara Langer and Lead Research Associate Kim MacDonnell will present on "Operational Challenges of Natural History Trials", at Gene Therapy for Rare Disorders conference in Boston, March 8-10.  Learn more. 

Article: Orphan Medicinal Products in the EU

If you are applying for an Orphan Drug Designation (ODD) for your rare disease therapy, there is great value in tapping into the regulatory tools and available interactions provided by the European Medicines Agency (EMA). Our latest paper recaps the support at hand. Learn more.

News: Supporting the Approval of Several Novel Therapies for Rare Diseases

We’re delighted to announce that Veristat supported Marketing Applications for 12% of all FDA Novel Drug Approvals (NDAs) in 2021. Our experience in complex drug development for rare and ultra-rare diseases significantly impacted these transformational medicines. Learn more.

Did you know Veristat raised >$350K for rare cancer research in 2021?

Team Veristat performed as the #2 fundraising team in the nation for Cycle for Survival last year, bringing our lifetime contributions to nearly $600,000. The Team will be participating again this May. Cycle on! 

Follow Veristat

Stay current with the latest news from Veristat by following us on social media using the links below.

CONTACT US

VERISTAT.COM